Supernus Pharmaceuticals, Inc. — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
SPN-817This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.	Épilepsie	Phase 2	À vérifier	United States, Australia	À vérifier
SPN-817This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.	Épilepsie	Phase 2	À vérifier	United States, Australia, Bulgaria, Hungary, Poland	À vérifier
SPN-817This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.	Épilepsie	Phase 2	À vérifier	United States, Australia	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
SPN-817	Épilepsie	Phase 2	NCT07141329	SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures	ENROLLING_BY_INVITATION
SPN-817	Épilepsie	Phase 2	NCT06798896	RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.